94 related articles for article (PubMed ID: 20795769)
1. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion.
Huh WW; Jaffe N; Durand JB; Munsell MF; Herzog CE
Pediatr Hematol Oncol; 2010 Oct; 27(7):546-57. PubMed ID: 20795769
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
3. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
Mladosievicova B; Foltinová A; Petrásová H; Bernadic M; Hulín I
Neoplasma; 2001; 48(1):61-5. PubMed ID: 11327539
[TBL] [Abstract][Full Text] [Related]
4. [Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin].
Geidel S; Garn M; Grävinghoff L; Hausdorf G; Morf G; Bielack S; Knop J; Winkler K
Klin Padiatr; 1991; 203(4):257-61. PubMed ID: 1942931
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef ML; Synold TW; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Yen Y; Groshen S; Johnson K; Lenz HJ; Gandara D; Doroshow JH
Clin Cancer Res; 2001 Jun; 7(6):1569-76. PubMed ID: 11410492
[TBL] [Abstract][Full Text] [Related]
6. Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.
FitzPatrick WM; Dervisis NG; Kitchell BE
Vet Comp Oncol; 2010 Dec; 8(4):273-82. PubMed ID: 21062409
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane.
de Matos Neto RP; Petrilli AS; Silva CM; Campos Filho O; Oporto VM; Gomes Lde F; Paiva MG; Carvalho AC; Moisés VA
Arq Bras Cardiol; 2006 Dec; 87(6):763-71. PubMed ID: 17262115
[TBL] [Abstract][Full Text] [Related]
8. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Sparano JA
Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
10. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?
Köseoğlu V; Berberoğlu S; Karademir S; Kismet E; Yurttutan N; Demirkaya E; Sungur M; Alehan D
Turk J Pediatr; 2005; 47(1):17-22. PubMed ID: 15884624
[TBL] [Abstract][Full Text] [Related]
11. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
12. N-terminal pro brain natriuretic peptide and cardiac function in doxorubicin administered pediatric patients.
Hongkan W; Soongswang J; Veerakul G; Sanpakit K; Punlee K; Rochanasiri W; Udompunturak S
J Med Assoc Thai; 2009 Nov; 92(11):1450-7. PubMed ID: 19938736
[TBL] [Abstract][Full Text] [Related]
13. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma.
Longhi A; Ferrari S; Bacci G; Specchia S
Anticancer Drugs; 2007 Jul; 18(6):737-44. PubMed ID: 17762406
[TBL] [Abstract][Full Text] [Related]
15. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
17. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
18. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
Swain SM; Whaley FS; Ewer MS
Cancer; 2003 Jun; 97(11):2869-79. PubMed ID: 12767102
[TBL] [Abstract][Full Text] [Related]
19. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
Lopez M
Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
[TBL] [Abstract][Full Text] [Related]
20. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]